IP Library Granted Patent US 10,369,145
Granted Patent B2
US 10,369,145 · App. 14/775,050 · Granted Aug 6, 2019

Coumarin derivatives and methods of use in treating hyperproliferative diseases

Inventors: Erik Schwiebert (Birmingham, AL); John Streiff (Birmingham, AL); John Dixon (Leicestershire, GB); Hongwu Gao (Shanghai, CN); Joseph P. Ritchie (Vestavia Hills, AL); Eric C. Seales (Birmingham, AL); Deborah Mai (Birmingham, AL)
Assignee: DISCOVERYBIOMED, INC.
A61K31/4709A61K31/422A61K31/427A61K31/4439C07D405/04C07D413/04C07D417/04C07D417/14C07D471/04C07D491/052C07D493/04C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,369,145
App. No.
14/775,050
Granted
Aug 6, 2019
Kind
B2
Abstract

Coumarin derivative compounds and methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The methods include administering to a subject a compound as described herein. Also provided are methods for inhibiting the interaction between two or more heat shock protein chaperones in a cell.

Claims (14)

1. A method for treating polycystic kidney disease in a subject, comprising:

administering to a subject an effective amount of a compound of the following formula:

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R 1 is hydrogen, halogen, substituted or unsubstituted amino, or substituted or unsubstituted C 1-6 alkyl;

R 2 is halogen, nitro, trifluoromethyl, substituted or unsubstituted amino, or substituted or unsubstituted C 1-6 alkyl; and

R 5 , R 6 , R 7 , R 8 , and R 9 are each independently selected from hydrogen, halogen, substituted or unsubstituted alkoxy, trifluoromethyl, or substituted or unsubstituted C 1-6 alkyl.

2. The method of claim 1 , wherein

R 2 is C 1-6 alkyl, halogen, or trifluoromethyl; and

R 5 , R 6 , R 7 , R 8 , and R 9 are each independently selected from hydrogen and methoxy.

3. The method of claim 1 , wherein R 5 is substituted or unsubstituted alkoxy.

4. The method of claim 1 , wherein the compound is

5. A method for treating polycystic kidney disease in a subject, comprising:

administering to a subject an effective amount of a compound selected from the group consisting of:

or a pharmaceutically acceptable salt or prodrug thereof.

Assignments (2)
CHANGE OF NAME Recorded Jan 19, 2024
From: DISCOVERYBIOMED, INC
To: AERONEPH THERAPEUTICS, INC.
Reel/Frame 066356/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2015
From: SCHWIEBERT, ERIK; STREIFF, JOHN; DIXON, JOHN; GAO, HONGWU; RITCHIE, JOSEPH P.; SEALES, ERIC C.; MAI, DEBORAH
To: DISCOVERYBIOMED, INC.
Reel/Frame 036543/0295 →
Continuity (2)
Provisional Application 61788398 · Mar 15, 2013
Related Publication 20160038475A1 · Feb 11, 2016